Actinium Pharmaceuticals
ATNM
63 hedge funds and large institutions have $7.66M invested in Actinium Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 11 increasing their positions, 22 reducing their positions, and 25 closing their positions.
9,800% more call options, than puts
Call options by funds: $99K | Put options by funds: $1K
9% less funds holding
Funds holding: 69 → 63 (-6)
8.72% less ownership
Funds ownership: 26.28% → 17.55% (-8.7%)
24% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 25
42% less capital invested
Capital invested by funds: $13.2M → $7.66M (-$5.53M)
50% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$993K |
| 2 |
Jane Street
New York
|
+$327K |
| 3 |
Renaissance Technologies
New York
|
+$227K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$147K |
| 5 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$97.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.21M |
| 2 |
State Street
Boston,
Massachusetts
|
-$633K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$572K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$555K |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
-$376K |
ATNM Hedge Fund Activity: Q2 2025 in Review
63 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2025, worth a combined $7.66M — down 42% from $13.2M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ATNM and 19 opened new positions — a net loss of 6 holders — while 22 trimmed existing stakes and 11 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $993K. The largest seller was BlackRock, cutting an estimated $2.21M.
- 63 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2025, down from 69 in Q1 2025.
- Funds reported $7.66M of Actinium Pharmaceuticals stock for Q2 2025, down 42% quarter-over-quarter.
- 19 funds opened new Actinium Pharmaceuticals positions in Q2 2025 and 25 closed out, a net change of -6 holders.
- The largest Actinium Pharmaceuticals buyer in Q2 2025 was Millennium Management, an estimated $993K added.
- The largest Actinium Pharmaceuticals seller in Q2 2025 was BlackRock, an estimated $2.21M sold.
Based on aggregated 13F filings for Q2 2025.